retatrutide sleep apnea Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Cuts Knee OA Pain

Media Influence: Media, including advertisements, TV shows, and movies, often promote fair-skinned individuals as the epitome of beauty

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF

A prospective case series study found that GLP-1RAs, such as liraglutide and exenatide, reduced the population of cutaneous T cells and the expression of IL-17 in skin lesions

Zittoun J, Farcet JP, Marquet J, Sultan C, Zittoun R